Fisetin

Fisetin (3,3',4',7-Tetrahydroxyflavone)

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

A flavonoid with preclinical fisetin senolytic evidence and registered human research without posted results. Human therapeutic efficacy, long-term safety, and a standardized dose remain unestablished.

Plain English

Fisetin is a plant flavonoid that researchers study for senolytic effects in cells and animals. Human fisetin trials have been registered, but registration is not the same as a positive result. Evidence from quercetin or dasatinib-plus-quercetin combinations cannot be used as evidence for fisetin alone, and no standard medical dose is established.

Overview

Fisetin is 3,3′,4′,7-tetrahydroxyflavone, a plant flavonoid studied for preclinical senolytic activity. It is distinct from cotinine, quercetin, dasatinib-plus-quercetin combinations, and other senolytic combinations. Human trial registrations may document planned research, but human therapeutic or senolytic efficacy and long-term safety are not established.

Research Summary

PMID 30279143 supports preclinical fisetin senotherapeutic/senolytic findings, including effects in cellular and animal models; it is not human efficacy evidence. NCT03430037 and NCT03675724 are exact fisetin intervention registry records involving older adults and are listed as registered trials without posted results. Their registry status must not be generalized into demonstrated senolytic efficacy, lifespan extension, or an established therapeutic regimen. Dasatinib-plus-quercetin and quercetin-alone evidence is excluded from this fisetin-alone record.

Research Areas

  • Preclinical senolytic research
  • Cellular senescence
  • Flavonoid pharmacology
  • Registered human research

Safety & Risks

Serious Risks

  • Long-term human safety data is absent — the doses used in some research studies substantially exceed what would be obtained from dietary sources
  • Potential drug interactions have not been systematically studied in humans
  • Not recommended during pregnancy or breastfeeding due to insufficient safety data
  • Bioavailability is a significant limitation: poor absorption may mean tissue concentrations after supplementation are substantially lower than doses shown to be active in preclinical studies
  • Supplement quality and purity vary considerably across commercial products

Reported Side Effects

  • Generally well tolerated in short-term studies
  • Mild gastrointestinal effects (nausea, abdominal discomfort) reported at higher doses
  • Long-term safety data in humans is limited
United States
No approved therapeutic fisetin product or indication is established by the sources represented in this record.
United Kingdom
No approved therapeutic fisetin product or indication is established by the sources represented in this record.
Australia
No approved therapeutic fisetin product or indication is established by the sources represented in this record.
Canada
No approved therapeutic fisetin product or indication is established by the sources represented in this record.

Citations & Sources